YKL-40, cardiovascular events, and mortality in individuals recently diagnosed with type 2 diabetes: A Danish cohort study

Alisa D. Kjaergaard*, Allan Vaag, Verena H. Jensen, Michael H. Olsen, Kurt Højlund, Peter Vestergaard, Torben Hansen, Reimar W. Thomsen, Niels Jessen

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

1 Downloads (Pure)

Abstract

Aims: We investigated the association of the inflammatory biomarker YKL-40 with cardiovascular events (CVEs) and mortality in individuals with type 2 diabetes. Methods: We followed 11,346 individuals recently diagnosed with type 2 diabetes for up to 14 years. Baseline YKL-40 levels (measured in 9,010 individuals) were grouped into percentiles (0–33 %, 34–66 %, 67–90 %, and 91–100 %) and analyzed continuously (per 1 SD log increment), with comparisons to CRP (measured in 9,644 individuals). Cox regression assessed associations with atrial fibrillation (AF), ischemic stroke (IS), venous thromboembolism (VTE), myocardial infarction (MI), heart failure (HF), peripheral artery disease (PAD), and all-cause, cardiovascular, and cancer mortality. Results: Adjusted HRs (95% CIs) for the highest (91–100%) versus the lowest (0–33%) YKL-40 percentile category were 1.31 (1.04–1.66) for AF, 1.43 (0.98–2.07) for IS, 1.07 (0.65–1.76) VTE, 0.88 (0.52–1.48) for MI, 1.66 (1.19–2.31) for HF, 1.66 (1.12–2.48) for PAD, and 2.18 (1.85–2.56) for all-cause, 1.64 (1.07–2.50) for cardiovascular, and 2.73 (2.05–3.63) for cancer mortality. Each 1 SD log increase in YKL-40 and CRP levels similarly increased CVE risks, with CRP being superior for MI and cardiovascular mortality. Conclusions: YKL-40 is a prognostic biomarker for most CVEs, and even more so for all-cause mortality, primarily driven by cancer-related causes.

OriginalsprogEngelsk
Artikelnummer111970
TidsskriftDiabetes Research and Clinical Practice
Vol/bind219
Antal sider9
ISSN0168-8227
DOI
StatusUdgivet - 2025

Bibliografisk note

Funding Information:
This work is supported by the Steno National Collaborative Grant (grant number: NNF20O0063292). The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project receives funding from the Danish Agency for Higher Education and Science [grant numbers 09\u2013067009, 09\u2013075724], the Danish Health Authority, the Danish Diabetes Association, and an unrestricted donation from Novo Nordisk A/S. A full list of project partners is available at https://dd2.dk/om-dd2/bevillinger.The funding sources had no involvement in the study's design, data collection, analysis, interpretation, or the writing of the report.

Publisher Copyright:
© 2024 The Authors

Citationsformater